CA2392917C - Pin1 as a marker for abnormal cell growth - Google Patents

Pin1 as a marker for abnormal cell growth Download PDF

Info

Publication number
CA2392917C
CA2392917C CA002392917A CA2392917A CA2392917C CA 2392917 C CA2392917 C CA 2392917C CA 002392917 A CA002392917 A CA 002392917A CA 2392917 A CA2392917 A CA 2392917A CA 2392917 C CA2392917 C CA 2392917C
Authority
CA
Canada
Prior art keywords
pinl
protein
cancer
activity
pin1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002392917A
Other languages
English (en)
French (fr)
Other versions
CA2392917A1 (en
Inventor
Kun Ping Lu
Gerburg Wulf
Xiao Zhen Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc filed Critical Beth Israel Deaconess Medical Center Inc
Publication of CA2392917A1 publication Critical patent/CA2392917A1/en
Application granted granted Critical
Publication of CA2392917C publication Critical patent/CA2392917C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
CA002392917A 1999-11-29 2000-11-29 Pin1 as a marker for abnormal cell growth Expired - Lifetime CA2392917C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16780099P 1999-11-29 1999-11-29
US60/167,800 1999-11-29
US25367600P 2000-11-28 2000-11-28
US60/253,676 2000-11-28
PCT/US2000/032560 WO2001038878A2 (en) 1999-11-29 2000-11-29 Pin1 as a marker for abnormal cell growth

Publications (2)

Publication Number Publication Date
CA2392917A1 CA2392917A1 (en) 2001-05-31
CA2392917C true CA2392917C (en) 2007-05-01

Family

ID=26863487

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002392917A Expired - Lifetime CA2392917C (en) 1999-11-29 2000-11-29 Pin1 as a marker for abnormal cell growth

Country Status (7)

Country Link
EP (1) EP1234185B1 (zh)
JP (1) JP2003515172A (zh)
AT (1) ATE400814T1 (zh)
CA (1) CA2392917C (zh)
DE (1) DE60039453D1 (zh)
HK (1) HK1051066A1 (zh)
WO (1) WO2001038878A2 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030073096A1 (en) * 2001-02-09 2003-04-17 Pintex Pharmaceuticals, Inc. Pin1 as a marker for prostate cancer
EP1368630A4 (en) * 2001-02-09 2004-06-16 Pintex Pharmaceuticals Inc PIN1 AS A MARKER FOR ABNORMAL CELL GROWTH
AU2002322199B2 (en) * 2001-09-12 2009-06-04 The Walter And Eliza Hall Institute Of Medical Research A method of diagnosis and treatment and agents useful for same
ATE261126T1 (de) 2002-08-01 2004-03-15 Mtm Lab Ag Verfahren für lösung-basierte diagnose
EP1572236A4 (en) 2002-11-14 2007-01-03 Pintex Pharmaceuticals Inc PINE RATE1 IN HEALTHY FABRIC AND IN CANCER FABRIC
WO2022032179A1 (en) * 2020-08-07 2022-02-10 The Regents Of The University Of California Pin1 inhibitors and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972697A (en) * 1995-11-13 1999-10-26 The Salk Institute For Biological Studies NIMA interacting proteins
US6495376B1 (en) * 1999-02-18 2002-12-17 Beth Israel Deaconess Medical Center Methods and compositions for regulating protein-protein interactions

Also Published As

Publication number Publication date
ATE400814T1 (de) 2008-07-15
DE60039453D1 (de) 2008-08-21
HK1051066A1 (zh) 2003-07-18
WO2001038878A2 (en) 2001-05-31
WO2001038878A3 (en) 2002-01-17
CA2392917A1 (en) 2001-05-31
EP1234185B1 (en) 2008-07-09
JP2003515172A (ja) 2003-04-22
EP1234185A2 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
US8129131B2 (en) Pin1 as a marker for abnormal cell growth
US20030157082A1 (en) Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules
US20030068626A1 (en) Pin1 as a marker for abnormal cell growth
CA2392917C (en) Pin1 as a marker for abnormal cell growth
AU1934701A (en) Pin1 as a marker for abnormal cell growth
AU2005209659A1 (en) Pin1 as a marker for abnormal cell growth
US20030108937A1 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
CN114591418A (zh) PPARγ蛋白的第166位苏氨酸磷酸化修饰及其应用
US7501255B2 (en) Levels of Pin1 in normal and cancerous tissue
US20060088880A1 (en) Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943
US10254283B2 (en) Biomarker for MELK activity and methods of using same
AU2002238068A1 (en) Pin1 as marker for abnormal cell growth
AU2014348780B2 (en) Biomarker for MELK activity and methods of using same
WO2004013634A2 (en) Dna damage repair polypeptide and uses thereof
US20070254830A1 (en) Interaction of Colon Cancer Related Gene C200RF20 With P120
US20060141473A1 (en) Erk7 and erk8, novel diagnostic markers for cancer
US20030113777A1 (en) Methods and compositions for the treatment and diagnosis of cellular proliferative disorders using 32222
US20030114408A1 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 86604
WO2001071352A2 (en) Compositions associated with complex formation

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20201130